
Τumor-informed vs Tumor-naïve
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
Liquid biopsies are a rapidly evolving diagnostic technology with numerous labs offering commercially available tests today. Most labs have taken an approach of cell-free (cfDNA)
GTC presented abstracts at ASCO 2023 GTC’s posters from 2023 Convention of American Society of Clinical Oncology are now available to be downloaded. Please reach
GTC presented abstracts at AACR 2023 GTC’s posters from 2023 Convention of American Association for Cancer Research are now available to be downloaded. Please reach
Baltimore, MD and Irvine, CA, April 13, 2023, Sysmex Inostics Inc., a subsidiary of Japan’s Sysmex Corporation and Baltimore-based biotechnology firm, and Genomic Testing Cooperative
Combining Longitudinal Real-World Data and Clinical Genomics Data Will Enable a More Precise Approach to Cancer Care and Research NEW YORK – COTA, Inc., an
CHICAGO – With the publication of a paper validating two artificial intelligence-based algorithms for assisting pathologists in molecular profiling of patients, the Genomic Testing Cooperative
Background VEXAS syndrome is a disease with inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the UBA1 gene affecting the Met41 residue of
Irvine, California– June 1, 2022 – Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting at the American Society of Clinical Oncology (ASCO)
IRVINE, California, May 25, 2022 – Genomic Testing Cooperative (GTC) today announced it received CE-IVD marks for its Hematology Profile Plus, Solid Tumor Plus as
Abstract Multiple studies have demonstrated that diffuse large B-cell lymphoma (DLBCL) can be divided into subgroups based on their biology; however, these biological subgroups overlap